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FUSION PEPTIDES FOR CONTROLLING ANTIMICROBIAL ACTIVITY 
ON BIOMEDICAL IMPLANTS 
SUMMARY 
Medical devices such as surgical implants have the potential to become infected with 
bacteria, leading to many medical problems including degeneration or rejection of 
the implant. The current treatment of infections is largely dependent on antibiotic 
therapy; however, traditional antibiotics are facing the increasing challenge of 
resistant bacterial mutants. A strong need is therefore present to develop effective 
anti-infectious implants as well as new antimicrobial drugs 
The family of antimicrobial peptide (AMP) is one of the promising candidates for 
infection prophylaxis and treatment. Many of them behave broad-spectrum activity 
towards Gram-positive and Gram-negative bacteria, viruses, fungi and some 
parasites. Because of their complex killing mechanisms, the possibility for AMPs to 
encounter a resistant bacterial strain is much lower than the conventional antibiotics.  
Modification of the implant surface with an antimicrobial agent is a potential routine 
to eliminate infections. Various techniques of immobilizing a biomolecule onto the 
metal surface have been reported; among them the affinity binding method in which 
the use of affinity tags to create fusion proteins that can bind to the desired surface 
has received special attention. In this field inorganic binding pepides offer wide 
range alternatives as a cross linker between biomolecule and metal suface.  
The goal of this research is to investigate if the selected AMP from the literature 
remain antimicrobial in the case of conjugation with HABP1 and if it is possible to 
develop antimicrobial implants for further steps of the research.  
Genetically engineered hydroxyapatite binding peptide (HABP) and antimicrobial 
peptide (AMP) that was selected from literature was synthesized conjugately for self 
immobilization on the model implant material, hydroxyapatite coated titanium 
surface. The fusion peptide and the AMP-modified titanium was further tested for 
their antibacterial activity against E.coli and S.mutans strains. According to results, 
the AMP-HABP1 fusion peptide has remarkable antimicrobial activity against both 
gram negative and positive bacteria and specific binding affinity to hydroxyapatite 
surfaces. When bound to hydroxyapatite coated titanium, it can be able to kill 
bacteria that interact with surface and prevent bacterial adhesion. 
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BİYOMEDİKAL İMPLANTLARDA ANTİMİKROBİYAL AKTİVİTEYİ 
KONTROL ETMEYE YÖNELİK FÜZYON PEPTİTLER 
ÖZET  
Biyoimplant malzemelerinin bakteriler tarafından enfekte edilme riski bulunmaktadır 
ve bu enfeksiyonlar implantın dejenerasyonu veya vücut tarafından reddedilmesi gibi 
problemlere neden olabilir. Günümüzde bu tür enfeksiyonların tedavisi büyük ölçüde 
antibiyotik temellidir; ancak uzun zamandan bu yana kullanılan geleneksel 
antibiyotikler bakteri mutantlarının geliştirdiği dirençle yüzleşmek zorunda kalmıştır. 
Bu nedenle yeni antibiyotiklerin ve ayni zamanda etkin antimikrobiyal implantlarin 
geliştirilmesine şiddetle ihtiyaç vardır. 
Antimikrobiyal peptidler enfeksiyonlar karsı savunma ve tedavi için umut verici 
adaylardan birisidir. Birçoğu gram pozitif ve negatif bakteriler, virusler, fungi ve 
bazı parazitleri de içine alan geniş bir aktiviteye sahiptir. Kompleks etki 
mekanizmalarından dolayı antimikrobiyal peptidlerin bakteriyel dirençle karşılaşma 
olasılıkları klasik antibiyotiklere göre daha düşüktür.  
Günümüzde implant yüzeyinin antimikrobiyal maddelerle kaplanması enfeksiyon 
riskine karşı koymada rutin bir işlem olarak önümüze çıkmaktadır. Biyomoleküllerin 
metal yüzeylere immobilizasyonu için birçok teknik rapor edilmiştir. Bunlar 
içerisinde istenen yüzeye bağlanabilen füzyon proteinler oluşturmak için “afinite 
tag”lerin kullanıldığı afinite ile bağlama yöntemi özellikle dikkat çekmiştir.Bu 
alanda inorganik yüzeylere afinitesi olan peptidler biyomolekül ve metal yüzey 
arasında çapraz bağlayıcı olarak geniş bir alternatif  listesi sunmaktadır. 
Bu çalışmanın amacı literatürden örnek olarak seçilen antimikrobiyal peptidin, 
hidroksiapatite spesifik bağlanan peptidle konjugasyonu ve ardından implant 
yüzeyine immobilizasyonundan sonra antimikrobiyal aktivitesini koruyup 
korumadığını test etmek ve antimikrobiyal implant geliştirme çalışmalarında 
potansiyel bir aday olup olmadığını göstermektir.  
Genetik olarak dizayn edilmiş hidroksiapatite spesifik bağlanan peptid (HABP) ve 
literatürden seçilmiş bir katyonik antimikrobiyal peptid model implat materyaline 
kendiliğinden immobilizasyon için konjuge olarak sentezlenmiştir. Daha sonra 
antimikrobiyal peptid ile kaplanmış titanyumun seçilen E.coli ve S.mutans suşlarına 
karşı antimikrobiyal aktivitesi test edilmiştir. Sonuçlar, AMP-HABP1 füzyon 
peptidin gram negatif ve gram pozitif bakterilere karşı kayda değer antimikrobiyal 
aktivitesi ve hidroksiapatit yüzeylere özel ilgisi olduğunu göstermektedir. 
Hidrokasiapatit kaplı titanyuma bağlı durumda yüzeyle etkileşen bakterileri 
öldürebilmekte ve bakteri adhesyonunu engellemektedir. 
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1.  INTRODUCTION AND BACKROUND 
1.1 Implant Materials 
The use of implant materials and  medical devices is an increasingly common and 
often life-saving procedure[1]. The past half century has seen explosive growth in the 
use of medical implants. Orthopedic, cardiac, oral, maxillofacial and plastic surgeons 
are only examples of medical specialists treating millions of patients each year by 
implanting devices as diverse as pace makers, artificial hip joints, breast implants, to 
dental implants and implantable hearing aids[1]  
Implant materials must be designed to minimise the adverse reactions associated with 
introducing a foreign material to the body.  The immune system will typically attack 
anything which has originated outside the body, leading to inflammation. It is 
therefore crucial to choose materials that will have a minimal negative impact on the 
body. 
Regardless of their composition or application, materials used for body repair must 
meet both biofunctionality and biocompatibility. Biofunctionality concerns the 
ability of the implant to perform the purpose for which it was designated. These 
requirements are: (i) mechanical properties such as tensile strength, fracture 
toughness, elongation at fracture, fatigue strength, Young’s modulus; (ii) physical 
properties such as density in case of orthopedic implants, or thermal expansion in the 
case of bone cement; and (iii) surface chemistry such as degradation resistance, 
oxidation, corrosion, or bone bonding ability [2]. Biocompatibility is defined as the 
ability of a material to perform with an appropriate host response in a specific 
application  [3].  
Various types of synthetic substitutes have been developed in order to comply with 
biofunctionality and biocompatibility. They belong to the following main material 
classes:                                                                          
(i) Metals such as titanium, titanium alloys, stainless steel, cobalt–chromium alloys. 
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(ii) Ceramics such as aluminum oxide, carbon, calcium phosphates, glass–ceramics. 
(iii) Polymers such as silicon, poly(methyl methacrylate), poly lactide, poly 
(urethane), ultra high molecular weight poly ethylene. 
(iv) Composites such as ceramic coating on metal implants, or ceramic-reinforced 
polymers[1]. 
Titanium is a standard material for medical devices such as hip joints, bone screws, 
knee joints, bone slides, dental implants, surgical devices, pacemaker cases and 
centrifuges due to its total resistance to attack by body fluids, high specific strength 
and low elastic modulus [1,4]. Commercially pure Ti-alloy is widely used in 
orthopedic and dental implants because of favorable mechanical properties, corrosion 
resistance[5]. In addition, the body readily accepts titanium since it is more 
biocompatible than stainless steel or cobalt chrome. However, Ti and its alloy are 
non-bioactive and it lacks in rapid tissue integration, which results in subsequent 
development of interfacial fibrous tissue and finally led to the isolation of the 
implants. Therefore, there is significant interest in the development of technologies 
that modify Ti surface for improving the interaction between bone cells and metal, a 
process called osseointegration[5] in order to improve patient outcomes. 
   
       Figure 1.1: Titanium Fixer and Screw. 
Hydroxyapatite (HA) coatings are applied to orthopedic and dental implants made of 
titanium (Ti) and its alloys in order to increase their bioactivities[6,7].HA coating on 
titanium can improve the bonding between the implant and host tissue, leading to 
uniform bone growth at the implant/bone interface.  
Hydroxyapatite is a naturally occurring mineral form of calcium apatite with the 
formula Ca5(PO4)3(OH), that is similar in composition to the mineral element in 
human bones. The enamel on teeth is largely composed of a form of this mineral. In 
nature, hydroxyapatite can appear to have brown, yellow, or green colorations. In its 
powder form, it is typically white.  
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Figure 1.2: Hydroxylapatite Crystals. 
This mineral is often used not only for titanium but also other medical implants. It is 
bioactive, meaning that it can integrate into bone structures and support growth 
without breaking down. Initially, the mineral was used mostly for dental implants. 
Although it is still used for this purpose today, it is also used for other purposes.  
Various methods of applying HA coatings have been developed for implants, such as 
plasma spraying, radio- frequency magnetron sputtering, dip coating, electrochemical 
deposition, pulsed-laser deposition, and electrophoresis deposition.  
Hydroxyapatite can also be used in instances where there are bone voids or defects. 
This process involves powders, blocks, or beads of the mineral being placed into or 
on the affected of areas of bone. Since it is bioactive, it induces the bone to grow and 
correct the problem. This process can be an alternative to bone grafts. It typically 
results in healing times that are shorter than they would be if hydroxyapatite was not 
used. 
In this study the model implant material, HA coated titanium slides. Surface coating 
was performed by the method of electro deposition at Material Science of Istanbul 
Technical University. The HA deposition and cross-sections were characterized 
using XRD, FTIR, Raman Spectroscopy  and FE-SEM at material science at Istanbul 
Technical University.  
1.1.1 Antibacterial Implant Materials 
The rapid progress of biomedical technology and an aging population places 
increasing demands on medical implants to treat serious tissue disorders and replace 
organ function. In the field of orthopedic implant surgery alone, about 2 million 
fracture-fixation devices and 600,000 joint prostheses are implanted every year in the 
United States [8]. 
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Medical devices such as surgical implants, catheters, hip replacements, and joint 
prostheses have the potential to become infected with bacteria, leading to many 
medical problems including degeneration or rejection of the implant.  
This problem is compounded by the alterations in host defenses associated with the 
peri-implant region which result in increased susceptibility to infection [9]. Further, 
it is well recognized that biomaterial surfaces themselves can support the growth of 
microorganisms which may form biofilms. Those colonies of microbes grow on 
medical implants and other devices and play a key role in the multi-billion-dollar-
per-year problem of antibiotic resistant infections. 
Such implant-associated infections are extremely resistant to antibiotics, host 
defenses [10], and frequently persist until the implant is removed. The risk of 
infection after surgical implantation ranges from 1% and 7%, but is associated with 
considerable morbidity, repeated surgeries, and prolonged therapy [11]. 
As mentioned above, infections are currently a major barrier to the long-term use of 
medical devices in treating various diseases and abnormalities. While many bacteria 
are particularly aggressive pathogens in their own right, once bacteria colonize a 
surface and differentiate into complex communities or biofilms, they become 
especially difficult to eradicate. Biofilms are considered the leading cause of up to 
400,000 cases of catheter-related, bloodstream infections each year In addition, 
biofilms can arise on virtually any device implanted in the body, including 
mechanical heart valves, contact lens, artificial hips and knees, and breast implants.  
Biofilms are a differentiated, high-density population of bacteria that are embedded 
in an extracellular polysaccharide matrix that protects the cells from stressful 
conditions such as desiccation and nutrient limitation. Biofilm formation is a two-
step process that requires the adhesion of bacteria to a surface followed by bacteria- 
bacteria adhesion, forming multiple layers of the bacteria [12]. Once a biofilm has 
formed, it can be very difficult to treat clinically because the bacteria on the interior 
of the biofilm are protected from phagocytosis and antibiotics. Biofilms represent a 
particular challenge for antibiotic therapy. Cells within a biofilm can be up to 1000 
times more resistant to antibiotics than planktonic forms [13]. For these reasons 
generally the affected device require to be removed surgically. 
Common causes of implant-associated infections are S. aureus and S. epidermidis   
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 [12,14].  S. aureus is a  common  cause of  metal- biomaterial, bone-joint,  and  soft-
tissue infections [12,15],  while  S. epidermidis is more  common with polymer 
associated implant infections [16]. Staphylococci are Gram-positive, nonmotile, 
nonspore forming facultative anaerobes that grow by aerobic respiration or 
fermentation, with diameters of 0.5−1.5 μm. They are characterized by individual 
cocci, which divide in more than one plane to form grape-like clusters. Staphylococci 
are often found among the normal flora of the human skin and mucous membranes. 
The staphylococci cell wall is composed of peptidoglycan and teichoic acids [12], 
and attached to which are adhesins and exotoxins. Many staphylococci strains, 
particularly S. epidermidis and some S. aureus strains, produce a biofilm[12]. 
Another one, S. mutans is a major cariogenic bacterium in the multispecies bacterial 
biofilm commonly known as dental plaque [17]. It is a Gram-positive, facultatively 
anaerobic bacterium commonly found in the human oral cavity and is a significant 
contributor to tooth decay. S. mutans produces copious amounts of extracellular 
polysaccharide, a key component of plaque and metabolism of sucrose rapidly 
produces an organic acid which demineralizes tooth enamel[18,19,20]. The S. 
mutans bacteria are facultative, that is, it can live with or without oxygen.  When the 
cells at the bottom of the plaque run out of oxygen, they switch from aerobic 
respiration to the fermentation of fructose, producing lactic acid which eventually 
breaks down teeth and causes cavities. These properties make these bacteria 
responsible for the infections related to dental implants. 
Prevention of such infections remains a priority [21].A new strategy for preventing 
implant-associated infections involves coating the implants with a polymer that 
contains common antibiotics. Such approaches are currently in clinical trials 
[21].However, the rising problem of infections caused by multiply antibiotic resistant 
bacteria, so-called superbugs, limits the value of this approach. In addition, the 
standard procedure for treating implant-associated infections using high doses of 
antibiotics over a long period of time, might exacerbate this situation by contributing 
to selection of antibiotic-resistant bacteria with potential life-threatening 
complications for patients [21].  The development of an implant coating with broad 
spectrum antimicrobial activity and one that has no relationship to common 
antibiotics would be highly advantageous. 
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Table 1.1: Different types of antibacterial coatings on titanium 
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1.2 Antimicrobial Peptides 
Antimicrobial peptides (AMP) are potential candidates as an alternative to traditional 
antibiotics. They have emerged as central components of the innate defenses of 
animals, insects, and plants, and peptides with activities against Gram-negative and 
Gram-positive bacteria, fungi, enveloped viruses, and eukaryotic parasites have been 
identified [22]. This group of peptides is generally short (<100 amino acid), form 
amphipathic structures, often cationic at physiological pH, and can be expressed 
either constitutively or inducibly by invading pathogens [23].  
AMPs are considered to be among the first line in host defense systems, in the sense 
that they not only can kill microbes directly but also are widely involved in the innate 
immune response. Many attempts have been made to utilize AMPs as novel 
antibiotics, because they exhibit a broad spectrum of antimicrobial activity and do 
not easily induce resistance compared to conventional antibiotics [24,25], although 
they do eventually evoke resistance [26]. Up to now, hundreds of AMPs have  been 
isolated  from  natural organisms, while even more have been synthesized in the 
laboratory. 
In this study, AMP was selected from a study performed by Hancock and his 
colleagues. They created a large library of peptides, and investigated the influence of 
charged and hydrophobic residues on the antimicrobial activity of tethered peptides, 
as well as the influence of their positioning within the peptide sequence relative to 
the tethering surface. From 127 peptides we used one of them, tet127 
(KRWWKWWRR) had approximately 90% activity against Pseudomonas 
aeruginosa while tethered on a substrate. These peptide is semi random one 
exhibiting potent antimicrobial activity in solution [27] and as tethered [22]. 
1.2.1 Discovery of Antimicrobial Peptides  
Antimicrobial peptides were discovered by two independent lines of work: 1) studies 
on mechanisms by which mammalian phagocytic cells kill bacteria; and 2) studies on 
the mechanism by which organisms kill bacteria for their survival. In the late 1870s 
scientists were searching for an agent to kill microbes without causing unacceptable 
damage to the hosts. Ehrlich, who called this agent a ―magic bullet‖, in the search for 
this agent started to work on mammalian granulocytes, and noted the different 
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staining characteristics of these cell [28].In 1883, Metchnikov described the 
involvement of granulocytes in the phagocytosis of microbes [29]. Two years later,  
Kanthack and Hardy discovered that the degranulation of granulocytes killed 
phagocytosed bacteria. In the following years Petterson found that aqueous extracts 
of pus from human emphysema had antimicrobial activity. Petterson and his 
coworkers desired to identify the compounds responsible for the antimicrobial 
activity. However, the techniques of the time were insufficient for further 
investigation of these antimicrobial agents [27]. Approximately two decades later, 
Fleming’s discovery of first lysozyme and then penicilin started a new era for the 
search of antimicrobial agents [29]. Ten years after the discovery of penicilin 
Hotchkiss and Dubos isolated tyrocidine and gramicidin antimicrobial peptides from 
Bacillus brevis, but only gramicidin could be used for very limited applications 
because of the cytotoxic activity of these antimicrobial peptides on eukaryotic cells. 
In following decades other antimicrobial peptides were isolated, such as mellitin 
from bee venom, but they too were toxic and hemolytic[30]. In 1969, Zeya and 
Spitznagel isolated five cationic antimicrobial proteins from rabbit polymorpho 
nuclear leukocytes that were not hemolytic, and found that cationic proteins 
permeate the bacterial cell because of their positive charge [31].In 1978, Weis and 
Elsbach reported the isolation of a protein, bacterial permeability inducing factor  
(BPI), from granule proteins of neutrophils of a chronic myelogenous leukemia 
patient. BPI had additional functions such as the neutralization of endotoxins besides 
its bactericidal activity [32]. In the early 1980s, cecropins were discovered after a 
decade of work [30]. Boman and his associates demonstrated  that the hymolymph of 
silk moth pupae had no antimicrobial activity, but the introduction of bacterial debris 
induced potent antimicrobial activity in the hymolymph. Subsequently, they 
associated this activity with cecropins and some other antimicrobial peptides such as 
attacins and lectins.  At first, it was thought that these antimicrobial peptides were 
unique to insects, but later they were isolated from other animals including mammals 
revealing that these peptides were widely distributed in the animal kingdom and 
provide enormous survival benefits to the host [33].Because these peptides are very 
potent against bacteria, but have no toxic or hemolytic effect on host cells, and have 
a wide taxonomic distribution, their discovery led to the start of a new era in studies 
of animal antimicrobial peptides [23, 34,35]. 
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1.2.2. Classification of Antimicrobial Peptides  
As was mentioned earlier, antimicrobial peptides were discovered as a result of two 
independent lines of work: first, studies on how mammalian phagocytic cells kill 
bacteria, and second, on how organisms kill bacteria. Therefore, in the past the origin 
of antimicrobial peptides was the basis for classification because this type of 
classification helped to make connections between the function of the antimicrobial 
peptides was the basis for classification because this type of classification helped to 
make connections between the function of the antimicrobial peptides originated from 
a similar group of animals and aspects of the living conditions of these animals. 
However the later discovery of a large number of peptides from many different 
animal species and the possession of a group of antimicrobial peptides, such as 
cecropins, by distantly related animal groups caused this type of classification to 
become futile. Today, a grouping approach based on the chemical and biochemical 
characteristics of peptides is preferred.  
These antimicrobial peptides can be subdivided by composition and secondary 
structure into four major groups. One group, including cecropins [36].and magainins 
[37], exhibit an a-helical structure in lipid membranes. Such peptides are often 
unordered in solution. A second group includes those, such as the defensins, that 
adopt an antiparallel b-sheet structure containing one or more disulfide bonds 
[38].The third group comprises those peptides forming looped structures containing 
one or more disulfide bonds such as bactenecin [39]. The fourth group involves 
peptides  that contain a  high percentage of  specific amino acids such as  the proline-
/arginine-rich bovine peptides, Bac5 and Bac7 [40] and the porcine peptide PR-39 
[41]. 
1.2.3 Mechanism of Action for Antimicrobial Peptides 
An essential requirement for any antimicrobial host defense or therapeutic agent is 
that it has a selective toxicity for the microbial target relative to the host. Ideally, 
such compounds have affinity for one or more microbial determinants that are easily 
accessible, common to a broad spectrum of microbes, and relatively immutable. 
Nature has apparently yielded a class of molecules that meets these constraints in the 
evolution of antimicrobial peptides. Antimicrobial peptides initially target microbial 
cells, and thus fulfill criteria outlined above for identifying molecular determinants 
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of pathogens that are accessible and broadly conserved. As a group, antimicrobial 
peptides have amphipathic features that mirror phospholipids, thus allowing them to 
interact with and exploit vulnerabilities inherent in essential microbial structures 
such as cell membranes[12]. 
The precise mechanism of action for antimicrobial peptides is yet to be explained. 
Nevertheless, studies show that prokaryotic membranes are recognized as targets by 
many antimicrobial peptides. Therefore, a number of models have been proposed to 
understand the mechanism of action of these peptides. According to one of the 
models, the mechanism involves the following steps: 1) electrostatic contact between 
a negatively charged membrane and positively charged antimicrobial peptide, 2) 
conformation of helical structure and insertion of the peptide into the membrane, and 
3) aggregation of several helices to form a pore. It was reported that a micromolar 
range of antimicrobial peptides sufficient to form a monolayer around a target cell 
was required for the lysis of bacteria and four or more peptides are required to 
aggregate and form pores, 5-40 Ǻ in diameter, large enough to kill a target cell. 
However, it was thought that an organism may be killed in different ways by 
different peptides, even if they are in the same structural class, or a peptide may 
operate by different mechanisms on different organisms [42].  
The detailed mechanisms are often very specific for a bacterial strain or group. For 
example, because of the different molecular composition of their cell surface, the 
alteration of surface charge as a resistance mechanism is accomplished by largely 
unrelated molecular procedures among Gram-positive and Gram-negative bacteria. 
A prominent mechanism of resistance in Gram-negative bacteria is the incorporation 
of positively charged aminoarabinose in lipid A, which reduces the anionic character 
of the cell surface and thus the attraction of cationic AMPs. In contrast, Gram-
positive bacteria, which do not have lipid A, achieve the same goal by modifying 
teichoic acids with D-alanyl groups or by including positively charged phospholipids 
in the cellular membrane [43]. 
The initial interaction with the target surface significantly influences subsequent 
peptide dynamics and membrane-disrupting effects. There is widespread acceptance 
that the initial mechanism by which antimicrobial peptides  target microbes occurs 
via an electrostatic interaction. The facts that electrostatic forces are active  over 
relatively long molecular distances and that lysine and arginine interactions with 
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phosphate groups in lipid bilayers are particularly strong likely contributes to the 
initial  attraction and  membrane-targeting  step many  antimicrobial peptides.  
 
Figure 1.3: Mechanism of Action for Antimicrobial Peptides. 
In the case of Gram-negative organisms, there is report suggested a mechanism of 
peptide interaction with membranes termed self-promoted uptake[44]. This 
mechanism, similar to that known for aminoglycoside antibiotics, contends that the 
initial action of the peptide involves a competitive displacement of LPS-associated 
divalent cations stabilizing the outer membrane. Such LPS displacement is likely to 
be energetically favorable given that the binding affinity of a typical antimicrobial 
peptide for LPS is ~3 orders of magnitude greater than that of divalent cations. This 
hypothesis is supported by studies with polymyxin-resistant pmrA strains of S. 
typhimurium. The LPS phosphate moiety in these strains is highly substituted with 4-
amino-4-deoxy-L-arabinose, providing the bacteria a reduced overall negative charge 
and corresponding increased resistance to cationic antimicrobial peptides[12]. In 
comparison, Gram-positive organisms lack an outer membrane or LPS; however 
their cell envelopes are enriched in negatively charged teichoic and teichuronic acids. 
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The significance of these anionic structures with respect to cationic antimicrobial 
peptide activity has been demonstrated using a mutant strain of S. aureus in which 
cell wall teichoic acid modification resulted in an increased negative surface charge 
and was associated with an increased sensitivity to killing by positively charged 
antimicrobial peptides. 
Antimicrobial peptides are preferentially more selective to the procaryotic cell 
membrane meaning that they selectively kill microorganisms without being 
significantly toxic to host cells. This might be because prokaryotic cell membranes 
are more anionic, and prokaryotic cell membranes do not have cholesterol. Studies 
showed that the presence of cholesterol in the artificial membranes significantly 
reduced the lytic activity of antimicrobial peptides. Research also demonstrated that 
besides the antibacterial activity antimicrobial peptides also possesses antitumor, 
antiviral and antiparasitical activity [45]. 
 
Figure 1.4: The membrane target of antimicrobial peptides of   multicellular 
……….…   organisms and   the basis of specificity [46]. 
1.2.4 Activity of Tethered Antimicrobial Peptide 
The activity and  mechanism of AMPs in solution have been studied for more than 
50 years. However, limited attention has been  paid to activities of AMPs that are 
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immobilized on a substrate. One of the earliest experiments by Haynie et al reported 
the antimicrobial activity of resin-tethered AMPs synthesized using a solid-phase 
strategy at the concentration of >1,000 μg/ml. The covalently-bonded AMPs were 
able to significantly reduce the number of viable cells and showed broad spectrum 
activity against pathogens [47]. 
A recent publication of Hilpert et al focused on the characterization of a group of 
highly active AMPs synthesized on a cellulose sheet [22]. The peptides from the 
most active class were found to show an inhibition rate of almost 100% against 
Pseudomonas aeruginosa (P. aeruginosa), even when they were restricted on the 
cellulose substrate. It was also observed that the activity of the tethered AMPs does 
not directly correspond with their analogs in free solution. Therefore, attention 
should be paid to the selection of AMP candidate when the peptide is delivered on a 
substrate. A higher surface density for most tethered AMPs was required  to  kill   the 
pathogens than the non-tethered AMPs.  
A most possible explanation is that immobilization results in limited mobility of the 
AMPs, reducing their ability to interact with or penetrate the bacterial membrane. 
Gabriel et al grafted a less effective AMP LL-37, the human cathelicidin, on a 
titanium substrate [48]. Antibacterial activity was only observed when the peptide 
was linked via a flexible poly(ethylene glycol) spacer, which provided improved 
lateral mobility over direct linking method and short linker coupling. As claimed by 
Bagheri et al, the most important factors affecting the activity of surface-bound 
peptide include the length of the spacer and the amount of target-accessible peptide 
[49]. However, it is speculated that a highly active peptide candidate may be able to 
compensate the negative parts of a rigid short linker, according to the positive results 
previously discussed from Hilpert et al.  
1.3 Modification of Implant Material With Antimicrobial Agents 
There is a number of immobilization strategies to make implant materials 
antimicrobial. The approaches can be divided into adsorption, covalent coupling, 
surface coating and affinity binding. These approaches were explained below on the 
model surface, titanium.  
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1.3.1 Adsorption 
Soaking the implant directly into a solution containing biomolecules is one of the 
simplest ways to attach the molecules onto titanium surface. In vivo test using the 
simple adsorption method for alkaline phosphatase delivery showed improved bone 
formation with the drug-adsorbed titanium implants [50]. Upon contact with air or 
water, titanium surface is rapidly oxidized with a rigid TiO2 layer, which is 
hydrophilic and weakly anionic at physiological pH. Proteins and other biomolecules 
can react with the oxide layer through van der Waals, hydrophobic or electrostatic 
forces. These interactions, however, are generally based on reversible phase 
equilibrium, and the adsorbed quantity and the subsequent release profile are largely 
dependent on the metal surface treatment,the soaking conditions and the external 
physiochemical environment.  
 
Figure 1.5: Schematic representation of adsorption immobilization. 
1.3.2 Surface Coating 
Surface coating on titanium implant can serve as a layer of active molecules alone, or 
can be incorporated with entrapped drugs as a delivery method. Calcium phosphate 
(CaP) coating is one of the most commonly utilized inorganic coatings. The mineral 
coating can be deposited onto implant surfaces by plasma spray, electrolytic 
deposition or biomimetic dip-coating techniques [56-60]. Organic components such 
as collagen and chitosan are usually co-deposited into the CaP coating to provide a 
mechanical reinforcement [61-65]. The porous coating can be further incorporated 
with drugs, proteins or growth factors to achieve different purposes [66]. 
Collagen and other organic components can be deposited onto titanium surfaces 
alone, serving as a bioactive layer or a drug delivery vehicle for a controlled release. 
Collagen is one of the most widely investigated extracellular matrix proteins and has 
an important role in promoting osteoblast adhesion and differentiation as well as  
controlling cell progression [67]. Schliephake et al studied the bone formation 
around a Ti screw  coated  with  collagen to which a  cell-adhesive peptide RGD 
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(Arg-Gly-Asp) was linked. Animal test model with dog mandibles showed 
significantly improved bone contact and increased volume density of the new bones 
with the drug-collagen coated screws [68]. 
Other organic coatings are also investigated utilizing different biomolecules. An 
animal study on rabbit was performed by Bumgardner et al with chitosan-coated 
titanium pins. The implants were inserted into the tibia of the rabbits, and the pins 
with chitosan coatings were proved more supportive for bone formation and 
osteointegration [69]. Poly(D,L-lactide) and politerefate coatings are reported to be 
potential candidates as well for controlled slow drug release [70]. 
1.3.3 Covalent Coupling 
Grafting biomolecules on titanium surfaces through covalent coupling provides a 
stable linkage, which can be retained for several days under physiological conditions 
[71,72]. This method is expected to retain the surface biomolecules for a longer 
period than the adsorption and coating delivery routines, and is receiving extensive 
attention from biomaterial researchers. 
Covalent coupling routine starts with the functionalization of the metal surface, 
usually through silanization. A bifunctional linker is subsequently conjugated onto 
the surface and links the biomolecules to the surface functional groups. The most 
commonly used crosslinkers are maleimides, which reacts with the thiol moiety in 
the cysteine residue more rapidly than with any other groups. This maleimide-
involving strategy can be used for cysteine immobilization, and more importantly, 
the covalent coupling of a bioactive peptide/protein that is linked with a cysteine end. 
 
Figure 1.6: Schematic representation of covalent immobilization. 
One of the applications for the covalent coupling strategy is the attachment of Arg-
Gly-Asp (RGD), a cell-adhesive peptide to titanium surface for modulating the 
adhesion of extracellular matrix (ECM) proteins. Xiao et al used three different 
heterobifunctional linkers to immobilize the RGD-cysteine peptide on silanized 
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titanium surfaces [73]. The silanization step was found to be the key step in 
controlling the loading reproducibility, and the surface peptide coverage is estimated 
to be similar regardless of the choice of linker. Ferris et al reported significant 
increase in new bone thickness and greater pull-out strength in rat femurs with Au-
coated titanium grafted with RGD compared with non-RGD implants [74], 
suggesting that this specific peptide is capable of maintaining its activity when 
tethered. RGD immobilized on a silicon surface through the same modification 
routine was also proved to enhance fibroblast adhesion and proliferation [75]. 
Besides cell-adhesive peptides, attempts have been made to graft antimicrobial 
molecules on titanium surfaces through covalent bonding as well. Vancomycin 
covalently bonded to titanium and Ti-6Al-4V alloy is reported to inhibit 
Staphylococcus aureus colony forming [76,77].  
1.3.4 Affinity Binding 
In affinity immobilization, biomolecule is immobilized via affinity interactions. A 
large number of affinity pairs such as lectin-sugar, antigen-antibody, and biotin-
avidin are known. Two versions of affinity immobilization are possible. In the first, 
the surface is precoupled to an affinity ligand and the target biomolecule is added. In 
the second, the biomolecule is conjugated to another molecule that in turn has 
affinity toward a surface. The use of affinity tags to create fusion proteins that can 
bind to the desired surface expands the list further. In this version, inorganic binding 
peptides conjugated to the target molecule can be used as a new approach. 
 
Figure 1.7: Schematic representation of affinity immobilization. 
1.4 Inorganic Binding Peptides 
In nature, proteins are reported to initiate, catalyze and mediate the fabrication of 
inorganic nano- and microstructures, which assemble into complex architectures. 
Therefore, a new emerging research field has been started in nanomaterials design 
termed molecular biomimetics and nanotechnology [78,79]. The organisms using the 
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organic-inorganic hybrid systems have evolved to use a part of their proteins in order 
to produce and bind the inorganic materials in vivo. These organisms synthesize 
inorganic binding proteins that bind and organize inorganic materials to highly 
ordered structures to perform excellent functions such as forming protective layers, 
supportive tissues, transferring ions and developing some optical and mechanical 
properties in favor of the organism.  
Some recent efforts have begun to identify small polypeptides that bind with high 
affinity to bulk materials using combinatorial biology approaches because of the 
limited occurrence of naturally inorganic associated proteins, Nowadays, peptide 
sequences specific to metals, metal oxides and semiconductors and their potential use 
in material assembly and synthesis[59] have been reported.  
The inorganic material commonly include magnetite (Fe3O4) particles in 
magnetotactic bacteria or teeth of chiton [80]; silica (SiO2) as skeletons of radiolarian 
[81] or tiny light-gathering lenses and optical wave guides in sponges [82]; 
hydroxyapatite (Ca2C(OH)3) in bones [83] and dental tissues of mammals [84] 
calcium carbonate (CaCO3) in the shells of mollusks [85]. 
For the selection of material-specific peptides, generally called genetically 
engineered peptides for inorganics, GEPI [78,79], phage [86] and cell surface display 
[87,88] have become the major in vivo techniques [89,90,91,87,92,93].  
Current approaches for biomolecule immobilization on glass or metal substrates 
generally require  surface functionalization by self-assembled monolayers (SAMs) of 
bifunctional molecules, such as aminoalkylalkoxysilanes for silica and carboxyl-
terminated alkanethiols for gold substrates. Despite their widespread utility, these 
traditionally available bifunctional molecules have certain limitations, such as 
causing random orientation of the protein on solid surface and requiring multistep 
chemical reactions, and the assembled monolayers can be unstable during 
immobilization. To overcome these limitations, it is preferable to have molecules as 
direct linkers to the solid substrate of interest that not only have all the desired 
features of the conventional chemically prepared SAMs but also have specificity to a 
given solid substrate and assemble onto it efficiently[94].An exciting alternative to 
chemical coupling may be the use of combinatorially-selected inorganic-binding 
peptides as molecular linkers and assemblers. In principal, in addition to the specific 
recognition of inorganic surfaces, combinatorially-selected inorganic-binding 
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peptides are robust and can be genetically engineered or modified to tailor their 
functionalities such as synthesizing, binding, erecting and linking of inorganic 
nanostructures[95]. 
There has been a surge of research activity utilizing these genetically engineered 
peptides for inorganics (GEPI), which could be used for synthesis, binding, 
assembly, and linking of inorganic nanostructures, all under ambient conditions[94]. 
Recently, peptide sequences specific for platinum, quartz, cuprous oxide and 
hydroxyapatite, as well as many other materials and minerals, have been identified 
[78,79, 96-101, 90-100, 92-101]. Those peptides have been also characterized in 
terms of binding kinetics, affinities, and molecular structure [90, 100,100 and 101].  
In terms of immobilization proseduce non-covalent methods has a drawback of 
leaving the biomolecule from the surface unrestrainedly and also for covalent 
methods there is need to modify the surface or biomolecule as disadvantage. Briefly, 
a novel alternative to current chemical coupling may be through the utility of 
combinatorial inorganic-binding peptides as specific molecular linkers. By this way, 
it is doable to make desired biomolecule capable of self immobilize onto inorganic 
surfaces selectively without any chemical treatment for surface activation.  
1.5 Model Implant Material: Hydroxyapatite Coated Titanium Slides 
Titanium and its alloys with various nanofunctionalized surfaces are used in dental 
and orthopedic applications. Surface preparation and hydroxyapatite coating is 
critical in bioactivation of these surfaces in order to enhance osseointegration.  
Titanium implant materials are not toxic nevertheless it is necessary to activate the 
surface. This can be achieved by alkaline treatment. Generated titanium oxide layer 
increases osseointegration and biocompatibility. Tissue response to titanium implants 
depends to chemical and physical properties of titanium. While the cavities which are 
100-150 diameters act as home for bone cells; narrower than 10µm are necessary for 
body fluid circulation. For these reasons the surface porosity and smoothness are 
critical in terms of osseointegration.  
HA coating of titanium/titanumoxide surface is required bioactivation by alkali 
treatment. Sodium titanate and titanium hydroxide groups polymerize on alkali 
surface and condensed as negatively charged titanium oxide at pH 7.4 [101]. During 
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the cathodic circulation, those compounds interact with calcium ions and form 
amorphous calcium titanate (ACT). 
In the course of anodic circulation, negatively charged phosphate groups form 
amorphous calcium phosphate (ACP – Ca9HPO4(PO4)5OH) by reacting with ACT 
and eventually, with the help of alkali surface conditions occurred during catodic 
coating , it form apatite crystal [99]. It is indicated that OCP and ACP are pilot of 
hydroxyapatite (HA) biomineralization and the surface tension of them are lower 
than HA in aqueous environment [99]. OCP is formed at acidic- neutral conditions, 
becomes instable and prefers hydroxyapatite formation. 
In this study, model implant material is ordered nanotubular titanium oxide slides 
coated with hydroxyapatite, prepared by Prof. Dr. Mustafa Urgen’s laboratory, 
material science and engineering department, Istanbul Technical University. 
By advanced treatments on pure titanium slides, ordered titanium dioxide 
nanotubular surfaces with 90nm average diameters, 2.5 micrometer deep were 
prepared [Seçkin and Urgen unpublished data]. Ordered titanium dioxide 
nanotubular plates were coated with calcium phosphate using a modified simulated 
body fluid (SBF) solution and pulsed electrodeposition process at 80ºC, with a 
current density of -10mA/cm
2
. Surface coating was characterized using XRD, FTIR 
and SEM, indicating formation of HA crystal [99]. 
In nature, hydroxyapatite exists only at the geologic sphere, so what generates the 
hydroxyapatite is its mineral forms. Hydroxyapatite which is in sclerenchyma may 
has reduced calcium, hydroxide and phosphate; Ca
+2
 may shuffle across with 
divalent and trivalent atoms; F
-
, OH
-
 ve CO3
–2
 may take the place of phosphate 
groups or HA may not be in the form as its  ideal stoichiometry. It is possible to be 
HA in other carbonated hydroxyapatite phases such as calcium phosphate oxide 
(CaO), calcium phosphate hydrate, calcium hydrogen phosphate hydroxide or 
Ca10(PO4)3(CO3)3(OH)2.  
Nanotubular titanium surface coating results demonstrated hydroxyapatite phases 
was formed. On the FE-SEM images (Fig.1.8), crystals which were in apicular 
morphology, 15nm diameter, 1,5 micrometer length, high level, spherical ordered 
dispersed uniformly. 
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Fig. 1.8: HA deposition on nanotubular titania, characterized by FE-SEM at  
……            ….. 80ºC[99]. 
Peaks that were given at XRD spectrum were compared with HA and CHA peaks 
given at ICSD 00–89–6437, 01– 89–7834 and 00–019-0272. 20–35θ included peaks 
typically similar to ones at ICSD datas (Fig 1.9).  XRD analysis of the coating 
indicated that Ha was deposited on the nanotubular titania slides. 
 
Fig. 1.9: HA deposition on nanotubular titania, characterized by XRD analysis[99]. 
FTIR spectrums belong to nanotubular  titanium oxide had  peaks of phosphate at 
569, 600, 962 at 1000–1200 cm-1 and OH peaks at  632 and 3568 cm–1 (Fig 1.10). 
Surface area of nanotubular titanium oxide slide is 80 times greater than flat 
titanium. It was reported that hydroxyapatite deposition on ordered titanium dioxide 
nanotubular slides can provide the alkali environment which is necessary for HA 
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formation since it has larger surface area that lets hydroxide ion generation and 
binding on surface. 
 
Fig 1.10: HA deposition on nanotubular titania, characterized by FT-IR 
…………spectroscopy [99]. 
1.6 Aim of the Study 
The main objective of this study is to investigate if the selected AMP from the 
literature maintains its antimicrobial property in the case of conjugation with HABP1 
and if it is possible to create self-immobilizing antimicrobial fusion peptide on 
hydroxyapatite surfaces, thus develop antimicrobial implants for further steps of the 
research. This includes antimicrobial activity assays of this fusion peptide in the free 
form, QCM experiments and anti-adhesive and antimicrobial effect of the fusion 
peptide tethered on the model implant material. 
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2.  MATERIALS AND METHODS  
2.1 Materials  
2.1.1 Bacterial Strains 
2.1.1.1 E. coli ATCC 25922 
E. coli ATCC 25922 was used in this study. The strain is not resistance to any 
antibiotics. 
2.1.1.2 S.mutans 
S.mutans was used in this study. The strain is not resistance to any antibiotics. 
2.1.2 Model Implant Material     
HA coated titanium slides (0.5x0.5cm) were prepared by cyclic electrochemical 
deposition at ITU Chemistry & Metallurgy Faculty Metallurgical & Materials 
Engineering Department by F. Şermin Utku and Eren Seçkin. 
 
Figure 2.1: HA coated titanium slide. 
2.1.3 Peptides   
HABP1 is a high affinity sequence, preferentially binds to hydroxyapatite surfaces, 
one of the genetically engineered peptides characterized by our collaborative group 
[100]. 
The peptides were kindly provided as lyophilized form. by Hilal Yazıcı from 
University of Washington 
HABP1       CMLPHHGAC 
AMP        KRWWKWWRR 
AMP-HABP1      KRWWKWWRR GGG CMLPHHGAC 
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2.1.4 Solutions & Medias 
2.1.4.1 Luria Bertani (LB) Medium 
10 g tryptone (Acumedia), 5 g yeast extract (Acumedia), 5 g NaCl (Riedel-de-Haen) 
were dissolved in distilled water and completed up to 1 lt. The pH was adjusted to 
7.0-7.5 with 10 M NaOH and sterilized for 15 min. under 1.5 atm at 121 °C. The 
medium was stored at room temperature.  
2.1.4.2 Brain Heart Infusion Medium 
37g Brain heart infusion broth (Fluka) was dissolved in distilled water and completed 
up to 1lt and sterilized for 15 minutes under 1.5 atm at 121°C The medium was 
stored at room temperature. 
2.1.4.3 E.coli ATCC 25922 Overnight Culture 
5 ml LB solution was inoculated with E. coli ATCC 25922 stock (from -80°C). The 
culture was left in the shaker overnight at 37°C, 200 rpm. The overnight culture was 
prepared freshly for each experiment. 
2.1.4.4 S.mutans Overnight Culture 
5 ml Brain Heart Infusion Broth solution was inoculated with S.mutans stock (from -
80°C). The culture was left in the shaker overnight at 37°C, 200 rpm. The overnight 
culture was prepared freshly for each experiment. 
2.1.4.5 Glycerol Stock Solution 
80 ml glycerol (Riedel-de-Haen) and 20 ml distilled water were mixed to get 80% 
(w/v) solution. It was sterilized for 15 minutes under 1.5 atm at 121
o
C. 
2.1.4.6  PC Buffer (Potassium Phosphate-Sodium Carbonate Buffer) 
55 mM KH2PO4 (Fisher), 45 mM Na2CO3 (Fisher), 200 mM NaCl (Sigma) were 
prepared in distilled water and the solution was sterilized by 0.2 μm single use 
syringe filter. The pH was adjusted to 7.2-7.5. 
Note: PC buffer can not be sterilized by autoclaving because CO3- ions are 
converted to CO2 due to high pressure during the autoclave. This conversion causes 
an increase in pH up to 10. 
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2.1.4.7 PBS (Phosphate Buffer Saline Buffer) 
37mM NaCl(Sigma), 2.7 mM KCl (Sigma), 10mM Na2HPO4(Fisher),  1.76mM 
KH2PO4(Fisher) were prepared in distilled water and the solution was sterilized by 
0.2 μm single use syringe filter. The pH was adjusted to 7.4.  
2.1.4.8 FITC Stock Solution 
6mg FITC (BioChemika) was dissolved in 1 ml PBS buffer and stored at +4
o
C. 
2.1.4.9 Ampicillin (Sodium Salt) stock solution 
1.28 mg Ampicillin (Sigma) was dissolved in 1 ml deionized water, sterilized by 
filtration using 0.22μm filter. This is a 1x stock solution and stored at -20oC. It is 
used as positive control for mibroth micro dilution assay. 
2.1.4.10 Cholaramphenicol Stock Solution 
1.28 mg Cholaramphenicol (Sigma) was dissolved in 1 ml deionized water, sterilized 
by filtration using 0.22μm filter. This is a 1x stock solution and stored at -20oC. It is 
used as positive control for broth micro dilution assay. 
2.1.4.11 Peptide Stock Solutions  
2.56 mg peptide was dissolved in 1 ml distilled water for each type of peptide. This 
is a 1x stock solution and stored at -20
o
C. 
2.1.5 Laboratory Equipments 
Autoclave: 2540 ML benchtop autoclave, Systec GmbH Labor- Systemtechnik. 
Automatic pipettes: Eppendorf. 
Centrifuges : Microfuge 18, Beckman Coulter. 
Confocal Microscope: Leica TCS SP2 SE Confocal Microscope. 
Deep freezes and refrigerators: Heto Polar Bear 4410 ultra freezer, 2021 D deep 
freezer, Arcelik., 1061 M refrigerator, Arcelik.  
Ice machine: AF 10, Scotsman. 
Laminar flow cabinet: Airclean 600 PCR Workstation ISC Bioexpress.     
Magnetic stirrer: AGE 10.0164, ARE 10.0162, VELP Scientifica srl. 
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Orbital shaker: Innova 3100 Water Bath Shaker New Brunswick Scientific 
pH meter: MP 220, Mettler Toledo  International Inc.: Inolab  pH level 1,  
order#1A10-1113,Wissenschaftlich-Technische Werkstätten GmbH & Co KG. 
QCM: KSV Z500 Finland. 
Spectrophotometer : DU530 Life Science UV/ Vis, Beckman, UV-1601, Shimadzu 
Corporation. 
Sterilizer : FN 500, Nuve. 
Vortexing machine: Reax Top, product# 541-10000, Heidolph2.2. 71. 
2.2 Methods 
2.2.1 Broth Micro Dilution Antibacterial Assay For Free Peptides 
The inhibition effect of the peptides versus their varying concentration was 
determined according to Broth Micro dilution Antibacterial Assay of Peptides. 
Briefly, serial dilutions of the peptides (256 µg/ml to 1 µg/ml ) were prepared in 96-
well microtiter slides and bacterial inoculum in their media was added to each well 
(∼5.0 × 104 CFU/well for E.coli and ∼1.0 × 104 CFU/well for S.Mutans ). Total 
volume was 200µl; 180µl was bacteria and 20µl was peptide solution prepared in 
dH2O. Slides were incubated at 37°C 16 to 20 hours and then optical density was 
monitored at 600 nm. Experiments were repeated three times in duplicate for each 
bacterial strain for E. coli and S.mutans. 
2.2.2 Modifying the Slides With Peptides 
Cleaned and sterilized (UV for 10min.) 0.5x0.5 HA-coated titanium slide was put in 
950 μl PC buffer containing 0.1 % detergent. Subsequently, 20 μl of peptide stock was 
added. The slide in the buffer solution was left overnight at room temperature with 
constant rotating. The detergent in the buffer provides the peptides to interact with 
the substrate surface individually.  
2.2.3 QCM Experiments 
A Quartz Crystal Microbalance (QCM) system (KSV Z500 Finland) was used to 
prove specific binding of AMP-HABP1 fusion peptide to hydroxyapatite. In a QCM,  
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quartz crystal is mechanically excited into a resonance by applying an alternating 
potential across two conducting films deposited on either side of the quartz crystal 
and the frequency of this oscillation is sensitive to the amount of adsorbed materials 
on the crystal surface [62]. Also QCM harnesses multiple frequencies which can be 
defined by overtone numbers n= 3,5,7,9 for determining the properties of the binding 
process. QCM device was connected to an oscillator circuit that has 5 MHz 
resonance frequency. In all experiments 7
th
 overtone was taken into account. 
In order to demonstrate the affinity of the fusion peptide to hydroxyapatite, an AT-
cut quartz crystal surface coated with hydroxyapatite was used. Control experiment 
was conducted with the same peptide on a bare quartz slide. Slides were cleaned with 
ultrasonication for 10 min each in isopropanol, ethanol and distilled water 
respectively. Finally, they rinsed with water again and dried under a stream of pure 
N2 before use.  To establish a stable baseline, a sufficient amount of PC buffer 
solution was introduced into the cell before adding the peptide solutions (AMP-
HABP1). After this initial treatment/measurement, the solution containing desired 
amount of peptide was injected into the cell and the frequency change was recorded 
continuously. 
2.2.4 Antimicrobial Activity on Surface 
2.2.4.1 Anti-adhesive Effect 
Bacterial adhesion characteristics of the functionalized titanium surfaces were 
assessed via the spread slide method. S.Mutans and E.coli were cultured in brain 
heart infusion broth and LB broth respectively. The bacteria were incubated 
overnight at 37 °C with agitation in the broth. An aliquot of bacterial culture was 
then added to the broth and incubated for another 2 h at 37 °C. The bacterial culture 
was centrifuged at 2700 rpm for 10 min. After the removal of the supernatant, the 
cells were washed twice with PBS and resuspended in PBS at a concentration of 
10
7
CFU/ml. 1 ml of the bacterial suspension was then added to each substrate in a 
24-well slide and incubated for 5 h/12h/24h  at 37 °C. The substrates were removed 
with sterile forceps and gently washed with PBS. The substrates were then placed in 
broth and the bacteria retained on substrates were dislodged by mild ultrasonication 
for 2 min in a ultrasonic bath, followed by rapid vortex mixing (10 s). Serial ten-fold 
dilutions were performed and viable counts were estimated using the spread slide 
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method. The number of  viable bacteria on each substrate surface was counted and 
expressed relative to the surface area of the substrate (number of bacteria/cm
2
). 
2.2.4.2 Bactericidal Effect 
E.coli and S.mutans were incubated as described above. The bacterial suspension as 
concentrated by centrifugation and resuspended in PBS at a concentration of  5 × 107 
CFU/ml; 1 ml of the bacteria suspension was added to each  substrate in  24-well 
E.coli and S.mutans were incubated as described above. The bacterial suspension 
was concentrated by centrifugation and resuspended in PBS at a concentration of 5 × 
10
7
 CFU/ml; 1 ml of the bacteria suspension was added to each substrate in 24-well 
slide. Slide chambers were covered and placed in a humidified incubator at 37°C; 
after 2 h, nonadherent bacteria were removed by with PBS [102].Adherent bacteria 
were stained with FITC (6 μg/ml) in PBS for 15 min at 37°C; FITC has been 
observed to only penetrate into cells with compromised membranes [102]. Slides 
were rinsed with PBS and imaged by confocal microscopy(Leica TCS SP2 SE).  
Fluorescent (488-nm band-pass filter for excitation of FITC) images were taken at 
identical locations to determine stained with FITC.  
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3.  RESULTS AND DISCUSSION  
3.1 Broth Microdilution Antibacterial Assay For Free Peptides 
In this study we used an inorganic binding peptide HABP1 (CMLPHHGAC) which 
was shown to have great binding affinity toward HA [100], a cationic peptide which 
was reported to have strong antimicrobial activity (KRWWKWWRR) [22] and a 
fusion peptide formed by conjugation of them, AMP-HABP1 
(KRWWKWWRRGGGCMLPHHGAC).  
The inhibition effect of the peptides versus their varying concentration was 
determined according to Broth Micro dilution Antibacterial Assay of Peptides. As it 
is shown in Figure 3.1 and 3.2, the fusion AMP-HABP1fusion peptide was not 
effective as AMP in solution against E.coli and S Mutans but it is clear that the 
fusion peptide had antibacterial activity. In addition, HABP1 partially inhibited 
bacterial reproduction. While an antimicrobial peptide killing the bacteria, it is 
generally accepted that it uses electrostatic interaction first. Hydroxyapaptite binding 
peptide 1 also has positively charged amino acid residue. So, it is possible to interact 
the HABP1 with bacteria membrane end damage it.  
 
Figure 3.1: Broth microdilution assay results for E.coli 5 × 107 CFU/ml 
………..……..incubated with peptides at  37°C for 16 hours. 
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As expected, conjugation with HABP1 decreases the antibacterial activity but it is 
shown that the new fusion peptide, AMP-HABP1, has remarkable activity against 
both gram negative and positive bacteria. The lower activity of the fusion peptide 
may be because positively charge density of antimicrobial peptide was decreased 
with the addition of HABP1 so it couldn’t interact with the negatively charged 
bacteria membrane as well as the antimicrobial peptide  
 
Figure 3.2: Broth microdilution assay results for S.mutans  5 × 107 CFU/ml 
……………incubated with  peptides 37°C for 16 hours. 
The figures 3.1 and 3.2 show that while AMP killed E.coli at the concentration of 
32µg/ml; S.mutans was almost killed at the concentration of 16µg/ml AMP (Figure 
3.1 and 3.1). Albeit the increasing concentration of HABP1-AMP up to 256 µg/ml 
there was no completely inhibition of bacteria reproduction compared to AMP. 
 
Figure 3.3: E.coli and S.mutans ratio after the incubation without (control) and with 
…………...AMP-HABP1 (256µg/ml) for 16 hours. 
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Under the experiment conditions, AMP-HABP1 killed %89,65 of the E. Coli and 
%75.96 of S. Mutans maximum (Figure 3.3). 
3.2 QCM  
Quartz is one member of a family of crystals that experience the piezoelectric effect. 
Quartz crystal is mechanically excited into a resonance by applying an alternating 
potential across two conducting films deposited on either side of the quartz crystal. 
The frequency of this oscillation is sensitive to the amount of adsorbed materials on 
the crystal surface. During normal operation, all the other influencing variables 
remain constant; thus mass change on the surfce correlates directly to a change in 
frequency. As mass is deposited on the surface of the crystal, the thickness increases; 
consequently the frequency of oscillation decreases from the initial value. By means 
of the resonant frequency shift, QCM can distinguish microgram of the mass added 
on the QCM electrode. Therefore it is termed microbalance. 
The affinity of AMP-HABP1 fusion peptide to hydroxyapatite surface was evaluated  
by the QCM experiment. First, the buffer solution was fed into  the system for 
system equilibirum. After the system came into balance, peptide solution prepared in 
the buffer solution was fed in order to monitor the binding property. Finally, by 
feeding the buffer again it was observed if the absorbed molecules on the surface 
dissociate or not. 
 
Figure 3.4: Frequency changes observed for 1µM AMP-HABP1 on quartz and 
……………hydroxyapatite  surface. 
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While evaluating the results it should be noted that all the biomolecules bind litte 
amount on any type of  surfaces but inorganic binding peptides have specific affinity 
only certain ones. With monitoring of frequency change which means the adsorbed 
mass on the surface, it can be said fusion peptide binds to hydroxyapatite specifically 
compared to bare quartz surface(Figure 3.4). After feeding PC buffer into the  system 
for the monitoring of dissosiation period of the adsorbed  peptide, it was observed 
that  there was no remarkable frequency increase  demonstrating that these fusion 
peptides remained on the surfaces. 
3.3 Antimicrobial Activity on Surface 
The fusion peptide was immobilized on the hydroxyapatite coated titanium surface 
through the high affinity of HABP1. Also the HABP1 was immobilized on the 
substrates to see whether it had any antimicrobial activity. Bacterial adhesion 
characteristics of the functionalized substrates were assessed via the spread slide 
method. Table 3.1 summaries numbers of bacteria adherent on the substrates. 
Table 3.1: Number of adherent of E.coli and S.mutans cells on surfaces of bare and 
…………   functionalized substrates. 
 Number of bacteria (CFU/cm2) 
5 Hours 12 Hours 24 Hours 
E
.C
o
li
 
HA coated Ti 800x10
3
 564x10
4
 610x10
4
 
HA coated Ti-
HABP1 
380x10
3
 456x10
4
 470x10
4
 
HA coated Ti-AMP-
HABP1 
8x10
3
 364x10
4
 188x10
4
 
S
.M
u
ta
n
s 
HA coated Ti 185x10
1
 380x10
1
 392x10
2
 
HA coated Ti-
HABP1 
56x10
1
 240x10
1
 260x10
2
 
HA coated Ti-AMP-
HABP1 
- 160x10
1
 246x10
2
 
For comparable results, relative bacteria numbers were calculated for E.coli (Figure 
3.5) and S.mutans (Figure 3.6). For 5 hours incubation the fusion peptide modified 
substrates were %100 effective for S.mutans while %99 for E.coli. However, this 
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effect decreased with time.  When they incubated for 12 hours nearly %32 of E.coli 
and %58 of S.mutans were blocked to attach on the surfaces and this percentage was 
lower when it was 24 hours. Although the decreased activity by the time, it is shown 
that the fusion peptide modified substrates effective for 24 hours in terms of anti 
adhesive property.   
It is also interesting that, despite it is not very hydrophobic or charged peptide, only 
the HABP1-modified substrates had anti adhesive activity but less than the fusion 
peptide modified ones. 
 
Figure 3.5: Number of adherent of E.coli cells on surfaces of bare and functionalized 
…………...substrates. 
 
Figure 3.6:  Number of adherent of S.mutans cells on surfaces of bare and ……   
…….………functionalized substrates. 
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As there is a growing need for alternative approaches to circumvent the limitations of 
antibiotic therapies, two approaches have been developed: materials with  
antimicrobial properties and materials with anti-adhesive properties. The first 
approach involves materials containing bactericidal substances that are incorporated 
into or bound to the biomaterial surfaces; the other approach is the modification of 
substrate materials with the anti-adhesives to prevent the adhesion of bacteria, thus, 
inhibiting biofilm formation and infection [101].  
To determine whether the decrease in bacteria on fusion peptide modified substrates 
resulted from the bactericidal or anti-adhesive effect of the surfaces, confocal 
microscope images were taken after staining with FITC. Experiments on modified 
HA coated titanium slides were performed by exposing the surfaces to an E. coli and 
S.mutans suspension for two hours and then rinsing to remove unattached and 
weakly attached bacteria. The bacteria remaining on the surfaces were imaged in 
fluorescence after staining with FITC to detect cells with compromised membranes.  
 
Figure 3.7: Confocal microscopy images for E.coli  after 2 h incubation on: bare HA  
… …….coated Ti (a) as control,  AMP-HABP1 modified HA coated Ti (b). 
 
Figure 3.8: Confocal microscopy images for S.mutans  after 2 h incubation on: bare 
…………..HA coated Ti (a) as control,  AMP-HABP1 modified HA coated Ti (b). 
FITC (molecular mass of 389.4 Da), a green fluorescent probe, can traverse only 
through the damaged cytoplasmic membrane of a cell[103]. 
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Images of representative areas of the substrates are shown in Figure 3.7 and 3.8. 
From these images, attached cells with compromised membranes (from FITC 
staining) were determined. 
We observed that FITC could penetrate only into cells that were treated with the 
fusion antimicrobial peptides tethered on surfaces that were active on them. The 
fluorescence images can only provide qualitative information about the effect of the 
functionalized surfaces. It means that fusion peptide modified hydroxyapatite coated 
titanium surfaces are able to damage the cell wall and kill the bacteria in first 2 
hours, thus provide antimicrobial activity. 
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4. CONCLUSION 
The rapid increase in the use of implantable biomedical devices requires the 
development of surfaces which can reduce the rate of colonization of the surface by 
microorganisms. Cationic peptides have previously been reported to meet the criteria 
for a successful antimicrobial surface coating. 
In the present study, the efficacy of binding of AMP-HABP1 was examined via 
affinity binding strategy applicable to a wide range of biomaterial surfaces and 
assesed as an antimicrobial surface.  
Selected AMP showed antimicrobial activity against to E. coli and S. mutans strains 
which is consistent with previous reports. It has been demonstrated that conjugation 
with HABP1 decreases the antibacterial activity but the new fusion peptide, AMP-
HABP1, has remarkable activity against both gram negative and positive bacteria. It 
may be due to attenuated positive charge density which is important for peptide and 
bacterial membrane interaction. Broth micro dilution assay shows it is possible to 
obtain a fusion peptide has remarkable antimicrobial activity and also QCM results 
indicate that this fusion peptide has specific binding affinity to hydroxyapatite 
surfaces. 
HA coated titanium surface modified with AMP-HABP1 showed reduced bacterial 
adhesion (total surface coverage by bacteria) and bactericidal effect for both strain of 
bacteria compared with blank ones. It can be said that the fusion peptide is active 
when attached to surfaces.  
Little is known about the mechanism of antimicrobial peptides tethered on surfaces 
but it is supposed that  when bacteria come into contact with these peptides, the 
bacteria loses its integrity and destroys itself [104]. 
This study shows that conjugation the antimicrobial peptides with one of the 
genetically engineered peptides, HABP1 make them capable of self-immobilization 
on the hydroxyapatite surfaces and may offer potential for development as a broad-
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spectrum antimicrobial coating for biomaterial surfaces, showing good activity 
against both gram-negative and gram-positive organisms.  
Development of antimicrobial surfaces for biomaterials is of great importance in 
reducing the clinical and economic burden of infection of medical devices and 
evaluation of methods of attachment for cationic peptides is critical to the 
development of effective antimicrobial surfaces. 
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